HLB펩

196300KOSDAQ

43.5 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Pep is a company specializing in the synthesis of amino acids, peptides, and proteins, offering CDMO (Contract Development and Manufacturing Organization) services for pharmaceutical production. Utilizing solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) technologies, the company manufactures APIs (Active Pharmaceutical Ingredients) for new drug development and clinical trials, adhering to GMP (Good Manufacturing Practice) and CMC (Chemistry, Manufacturing, and Controls) standards.

Number of Employees

88people

Average Salary

35.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.59Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-4.13Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

2.72Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼4.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼7.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -55.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 4,305Won52-week high 9,40052-week low 3,715

1-month return3.0Point

1m -0.69% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-08-20
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-20
Neutral반기보고서 (2026.06)2026-08-13
Neutral전환청구권행사 (제3회차)2026-08-12